Ignite Creation Date:
2024-07-17 @ 10:41 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06491576
Status:
COMPLETED
Last Update Posted:
2024-07-09
First Post:
2024-05-30
Brief Title:
A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis
Sponsor:
Burgeon Therapeutics Co Ltd
Organization:
Burgeon Therapeutics Co Ltd
Study Overview
Official Title:
A Single-center Randomized Double-blind Multiple Ascending Dose Placebo-controlled Phase IbIIa Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics and Early Pharmacodynamics of BGT-002 Tablets in Subjects With NASH
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center randomized double-blind multiple ascending doses MAD placebo-controlled phase IbIIa clinical trial of BGT-002 Tablets in subjects with NASH to evaluate the safety tolerability pharmacokinetics PK and early pharmacodynamics PD of BGT-002 Tablets
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None